Compounded GLP-1 medicines: what pharmacy learners should check

FDA's current concerns page includes adverse-event information through May 31, 2026, while its compounding-policy clarification includes an April 1, 2026 update. These make the subject relevant to current US pharmacy study. They do not prove that a particular question will appear on NAPLEX or that search demand is rising.

The July 2024 dosing-error alert remains useful background, but it should not be described as a new 2026 alert. Separate the date of a source from the date you read it. This brief was checked October 4, 2026 and links the primary sources so a reader can check later changes.

FDA says compounded drugs do not undergo its premarket review for safety, effectiveness and quality. A compounded preparation should not be described as an FDA-approved generic simply because it contains a similarly named ingredient. FDA also identifies concerns with salt forms of semaglutide, fraudulent labels and illegal online sales.

Compounding availability depends on the relevant federal conditions and current circumstances. FDA's April 2026 clarification states that semaglutide and tirzepatide do not currently appear on its shortage list or the 503B bulks list. That statement does not mean every conceivable patient-specific preparation is automatically lawful or unlawful. Read the complete current guidance; this article is not legal advice or an instruction to compound.

FDA's dosing alert describes confusion between milligrams, milliliters and syringe 'units', as well as products supplied at different concentrations. An amount in mg must be converted using the actual mg/mL concentration. A syringe marking indicates a volume scale; it is not an independent statement of semaglutide mass.

For a hypothetical non-drug-specific arithmetic example, a 0.6 mg amount from 2 mg/mL requires 0.3 mL. At 4 mg/mL, the same amount requires 0.15 mL. Reusing the first volume after a concentration change would double the amount. These invented numbers are not a semaglutide dose, titration schedule or self-injection instruction.

A useful pharmacy case should supply the product identity, verified concentration, ordered amount and appropriate measuring device information. If the instruction merely says 'ten units' without a clear product-specific volume and concentration relationship, clarify it rather than copying a conversion from another vial or online chart.

FDA encourages health professionals to provide an appropriate syringe and counseling, and to contact the compounder when the calculation is uncertain. For exam reasoning, identify the unsafe assumption and the clarification needed. For actual treatment or a suspected dosing error, contact the patient's treating professional; this article cannot assess or manage an individual case.

FDA's current page reports adverse events associated with compounded products and warns that reporting may be incomplete. It also says it is not always possible to determine whether the drug caused an event. Report counts are not an incidence rate, a comparative trial result or proof of causation.

Use this topic to practise medication-use verification, concentration calculations and source appraisal, all of which fit the broader NABP outline. The free questions and calculation lessons linked below are study routes, not endorsements of a product or promises of exam success. No person pictured is presented as a NAPLEX Bank clinician or reviewer.

Try it before reading the answer

Write your setup, units and check first. These are original practice exercises, not recalled exam items.

Continue learning